varnincabtagene autoleucel + cesnicabtagene autoleucel

**Varnincabtagene autoleucel + cesnicabtagene autoleucel** is a combination of two autologous CAR-T cell therapies investigated for potential synergistic effects in B-cell malignancies, though no specific clinical data or trials directly evaluating this exact pairing were identified. Varnincabtagene autoleucel (IMN-003A or ARI-0001) is a second-generation CD19-directed CAR-T with a 4-1BB costimulatory domain and non-FMC63 binder, manufactured point-of-care, primarily for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). Cesnicabtagene autoleucel lacks detailed public records but follows autoleucel naming for T-cell products; it may target a distinct antigen (potentially CD19 or another B-cell marker) to complement varnimcabtagene in dual CAR-T approaches. No developer, approval, or efficacy data specific to the combination exists in available sources.